NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-237-2017-2-NZ-04 T CELL RECEPTORS RECOGNIZING MUTATED P53 NZ DIV 803564 Pending
NCI E-237-2017-2-NZ-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 NZ DIV 803561 Pending
NCI E-237-2017-2-NZ-02 T CELL RECEPTORS RECOGNIZING MUTATED P53 NZ DIV 803557 Pending
NIAID E-081-2013-4-US-01 PREFUSION RSV F PROTEINS AND THEIR USE US CON 18/464,786 11981707 Issued PDF
NIDDK E-051-2021-0-CN-01 HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS CN National Stage 202280020636.5 Abandoned
NCI E-040-2012-0-JP-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen JP DIV 2023-146498 Pending
NIAID E-037-2021-1-KR-11 Antibodies Targeting The Spike Protein Of Coronaviruses KR National Stage 10-2023-7030836 Pending
NIAID E-031-2026-0-JP-02 Antigenic Epstein Barr Virus Polypeptides JP DIV 2023-145164 Issued
CC E-096-2016-0-US-04 POWERED GAIT ASSISTANCE SYSTEMS US CON 18/243,573 Pending
NIAID E-260-2014-0-US-07 RECOMBINANT METAPNEUMOVIRUS F PROTEINS AND THEIR USE US DIV 18/462,340 12233124 Issued PDF
NIAID E-185-2022-0-PC-01 Engineered SARS-CoV-2 Antibodies With Increased Neutralization Breadth PCT PCT PCT/US2023/073517 Expired
NIAID E-102-2022-0-US-01 HUMAN PARAINFLUENZA VIRUS IMMUNOGENIC MOLECULES US 63/580,772 Expired
NIAID E-214-2021-2-IN-01 Self-assembling Nanoparticles Based On Amphiphilic Peptides IN National Stage 202317059300 Pending
NICHD E-058-2021-0-AU-01 La Protein As A Novel Regulator Of Osteoclastogenesis AU National Stage 2022230408 Pending
NIAID E-183-2022-0-PC-01 NANOPARTICLE-DERIVED VACCINES AGAINST POXVIRUSES, AND METHODS FOR MAKING AND USING THE SAME PCT PCT PCT/US2023/031683 Expired
NCATS E-039-2021-0-CA-01 METHODS AND SYSTEMS FOR SOLID PHASE EXTRACTION CA National Stage 3212492 Pending
NCI E-169-2022-0-PC-01 Single Domain Antibodies Targeting HPV E6/E7 Oncogenic Peptide/MHC Complexes PCT PCT PCT/US2023/073144 Expired
NICHD E-058-2021-0-US-02 La Protein As A Novel Regulator Of Osteoclastogenesis US National Stage 18/279,476 Abandoned
NIAID E-007-2015-0-US-02 CD47-targeted Therapies For The Treatment Of Infectious Disease US CON 18/458,903 Pending
NCI E-064-2021-0-EP-01 Adjuvanted Mucosal Subunit Vaccines For Preventing SARS-CoV-2 Transmission And Infection EP National Stage 22705675.1 Pending
NCI E-181-2017-0-NZ-01 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS NZ DIV 803139 Pending
NCI E-237-2023-0-US-01 SCAVENGER RECEPTOR-A1 TARGETED LIPID NANOPARTICLE FOR APC DELIVERY OF
MRNA VACCINES 		US 63/535,215 Expired
NCI E-175-2016-0-HK-01 ANTI-KRAS-G12D T CELL RECEPTORS HK EP 42023078137.9 Pending
NICHD E-058-2021-0-CA-01 La Protein As A Novel Regulator Of Osteoclastogenesis CA National Stage 3211983 Pending
NIAID E-001-2024-1-US-01 Viral Strain Serology Assays US 63/578,685 Expired
NCI E-150-2017-2-US-01 Diagnostic Methods For T Cell Therapy US CON 18/455,033 Pending
NCATS E-204-2022-4-US-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF US 63/578,386 Expired
NIAID E-205-2024-0-US-01 Human Protective Neutralizing and Non-Neutralizing Antibodies and Their Use Against Influenza Viruses US 63/578,505 Expired
NIAID E-037-2021-1-EP-07 Antibodies Targeting The Spike Protein Of Coronaviruses EP National Stage 22705961.5 Pending
NCATS E-244-2014-0-CA-01 Small Molecule Inhibitors Of Lactate Dehydrogenase and Methods of Use Thereof CA DIV 3210002 Pending
NCI E-494-2013-0-HK-01 Methods of Preparing Anti-human Papillomavirus Antigen T Cells HK EP 42023077832.6 Pending
NCI E-285-2016-2-JP-01 Glypican 2 As A Cancer Marker And Therapeutic Target JP DIV 2023-133443 Issued
NCI E-239-2017-0-JP-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS JP DIV 2023-133670 Issued
NIAID E-240-2023-0-PC-01 VACCINES AGAINST CORONAVIRUSES PCT PCT PCT/US2023/030602 Expired
NIAID E-045-2021-0-US-02 NOVEL COMPOSITIONS OF MATTER COMPRISING STABILIZED CORONAVIRUS ANTIGENS AND THEIR USE US National Stage 18/277,921 Pending
NLM E-111-2016-9-US-03 NOVEL CRISPR ENZYMES AND SYSTEMS US CON 18/235,760 Pending
NCATS E-072-2021-0-US-02 FUNCTIONAL BRAIN REGION-SPECIFIC NEURAL SPHEROIDS AND METHODS OF USE US National Stage 18/547,037 Pending
NIAMS E-244-2020-0-CA-01 SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2 CA National Stage 3209052 Pending
NIAMS E-244-2020-0-AU-01 SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2 AU National Stage 2022224636 Pending
NEI E-013-2021-0-CN-02 COMPOSITION AND METHOD OF PRESERVING VIABILITY OF CELL IN A LOW TEMPERATURE CN National Stage 202180094031.6 Pending
NCI E-078-2012-0-CA-01 Anti-Mesothelin Chimeric Antigen Receptors CA DIV 3209571 Pending
NIAMS E-244-2020-0-IL-01 SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2 IL National Stage 305301 Abandoned
NIAID E-240-2023-0-EP-01 VACCINES AGAINST CORONAVIRUSES EP ORD 23315318.8 Pending
NCI E-174-2022-0-PC-01 Synergistic Interactions For Improved Cancer Treatment PCT PCT PCT/US2023/072333 Expired
NCI E-029-2021-0-US-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 US National Stage 18/277,521 Pending
NCATS E-047-2021-0-CN-01 MULTI-CYCLC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF CN National Stage 202180093913.0 Pending
NHLBI E-134-2022-0-PC-01 SYSTEMS AND METHODS FOR ELECTROCARDIOGRAPHIC RADIAL DEPTH
NAVIGATION OF INTRACARDIAC DEVICES 		PCT PCT PCT/US2023/072161 Expired
NIAID E-214-2021-2-US-01 Self-assembling Nanoparticles Based On Amphiphilic Peptides US National Stage 18/277,220 Pending
NEI E-192-2014-1-US-01 Surgical Tool And Method For Soft Ocular Tissue Transplantation US CON 18/233,654 Pending
NIAID E-214-2021-2-JP-01 Self-assembling Nanoparticles Based On Amphiphilic Peptides JP National Stage 2023-548865 Pending